Dumont & Blake Investment Advisors LLC Sells 48 Shares of Amgen Inc. (NASDAQ:AMGN)

Dumont & Blake Investment Advisors LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 8,849 shares of the medical research company’s stock after selling 48 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in Amgen were worth $2,306,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sanctuary Advisors LLC bought a new position in shares of Amgen during the 2nd quarter worth approximately $21,049,000. Newbridge Financial Services Group Inc. boosted its holdings in shares of Amgen by 99.1% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 840 shares of the medical research company’s stock worth $263,000 after buying an additional 418 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Amgen during the 2nd quarter worth about $16,515,000. Anchor Investment Management LLC boosted its holdings in shares of Amgen by 3.1% during the 2nd quarter. Anchor Investment Management LLC now owns 6,211 shares of the medical research company’s stock worth $1,941,000 after buying an additional 187 shares during the period. Finally, Centaurus Financial Inc. boosted its holdings in shares of Amgen by 16.8% during the 2nd quarter. Centaurus Financial Inc. now owns 1,615 shares of the medical research company’s stock worth $505,000 after buying an additional 232 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $284.02 on Friday. The stock has a market cap of $152.67 billion, a P/E ratio of 36.37, a price-to-earnings-growth ratio of 2.78 and a beta of 0.56. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The stock’s 50-day moving average is $271.35 and its 200-day moving average is $304.99. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The company’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.96 EPS. Equities research analysts anticipate that Amgen Inc. will post 19.56 earnings per share for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.35%. Amgen’s payout ratio is presently 115.24%.

Analysts Set New Price Targets

Several research firms have weighed in on AMGN. Deutsche Bank Aktiengesellschaft lowered their price objective on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. TD Cowen boosted their price objective on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a report on Monday, October 21st. Barclays raised their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Finally, UBS Group lowered their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $314.00.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.